Truceb-E Tablet
Erdosteine 300 mg + Acebrophylline 100 mg Tablets
| Composition | Erdosteine 300 mg + Acebrophylline 100 mg |
|---|---|
| Dosage Form | Tablet |
| Pack Type | Alu-Alu Blister |
| Pack Size | 10 x 10 Tablets |
| MRP | ₹ 5990 |
| Therapy | Pulmonology / Chest — Mucolytic + Mucoregulator-Bronchodilator |
| Storage | Store below 30 °C in a dry place, protected from light and moisture. Keep out of reach of children. |
📱 WhatsApp Enquiry📞 Call: +919041677932
About Truceb-E Tablet
Truceb-E Tablet combines Erdosteine 300 mg with Acebrophylline 100 mg — a dual-action mucolytic and bronchodilator regimen for obstructive airway diseases associated with thick, viscid, difficult-to-clear mucus. Manufactured by Trumac Healthcare under WHO-GMP certified conditions and packed in moisture-resistant Alu-Alu blisters to protect against humidity during Indian climatic transit.
Erdosteine breaks disulphide bonds in mucus glycoproteins to reduce sputum viscosity and improve mucociliary clearance, and its metabolite provides antioxidant free-radical scavenging that limits airway inflammation. Acebrophylline acts as both a bronchodilator (via its theophylline-7-acetate moiety) and a mucoregulator (via its ambroxol moiety) — relaxing bronchial smooth muscle, stimulating surfactant production and reducing airway hyper-reactivity.
Together, the two molecules improve airflow, ease expectoration, relieve breathlessness and wheezing, and help reduce exacerbation frequency in chronic bronchitis, COPD, asthma with mucus plugging, bronchiectasis and chronic productive cough. Truceb-E is available for pan-India monopoly PCD franchise and third-party manufacturing.
Indications
- Chronic bronchitis and acute exacerbations of chronic bronchitis
- Chronic obstructive pulmonary disease (COPD) with mucus hypersecretion
- Bronchial asthma with mucus plugging
- Bronchiectasis with viscid secretions
- Chronic productive cough of infective, allergic or irritative origin
- Post-tracheobronchial infection recovery to clear residual secretions
Mechanism of Action
Erdosteine is a pro-drug whose active metabolite (Met-1) contains free thiol groups that cleave the disulphide bridges of mucus glycoproteins, reducing sputum viscosity and elasticity and improving mucociliary transport. Met-1 also acts as a free-radical scavenger, protecting the bronchial epithelium from oxidative stress driven by cigarette smoke and neutrophilic inflammation, and it enhances antibiotic penetration into bronchial secretions. Acebrophylline is a molecular salt of ambroxol and theophylline-7-acetate — the ambroxol moiety depolymerises acid mucopolysaccharide fibres in mucus and stimulates alveolar surfactant secretion, while the theophylline component inhibits phosphodiesterase and antagonises adenosine receptors on bronchial smooth muscle, producing bronchodilation and reducing airway hyper-reactivity. The two mechanisms complement each other — Erdosteine liquefies existing mucus and neutralises oxidative injury, while Acebrophylline opens the airways and helps regulate future mucus production.
Dosage & Administration
Adults: 1 tablet twice daily after meals, or as directed by the treating physician. Duration is typically 5–10 days for acute exacerbations and may be extended in chronic maintenance therapy per clinical judgement. Not recommended for children below 12 years unless specifically advised by a paediatric pulmonologist. Dose adjustment may be required in severe hepatic impairment. Complete the prescribed course even if symptoms improve. Take with a glass of water; may be taken with food to improve GI tolerance.
Side Effects
Generally well tolerated. Reported effects include: nausea, dyspepsia, epigastric discomfort, altered taste; headache, dizziness; mild tremor, palpitations and tachycardia (xanthine-related, dose-dependent); rare skin rash or hypersensitivity; rare mild rise in liver enzymes. Discontinue and consult physician if severe rash, chest pain, marked tachyarrhythmia or persistent GI symptoms occur.
Contraindications & Precautions
Known hypersensitivity to Erdosteine, Acebrophylline, ambroxol, theophylline or any excipient. Severe hepatic impairment. Severe cardiac arrhythmia. Active peptic ulcer disease. Uncontrolled hyperthyroidism. Seizure disorders (relative — xanthines lower seizure threshold). Homocystinuria. Pregnancy and lactation — use only if the potential benefit outweighs the risk, under specialist supervision. Concomitant use of xanthine-containing preparations or CYP1A2 inhibitors (e.g. fluvoxamine, ciprofloxacin) may increase theophylline levels — dose adjustment or monitoring recommended.
Storage
Store below 30 °C in a dry place, protected from light and moisture. Keep out of reach of children.
Truceb-E Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Truceb-E Tablet used for?
Truceb-E Tablet is a dual-action mucolytic + bronchodilator combination of Erdosteine 300 mg and Acebrophylline 100 mg. It is used to manage obstructive airway diseases with thick, sticky mucus — including chronic bronchitis, COPD exacerbations, asthma with mucus plugging, bronchiectasis and chronic productive cough. It helps loosen and clear phlegm while also opening up the airways.
How does Truceb-E work?
Erdosteine breaks the disulphide bonds that hold mucus together, making it thinner and easier to cough out, and its metabolite also scavenges free radicals that damage airway tissue. Acebrophylline relaxes the bronchial smooth muscle (bronchodilator effect from its theophylline component) and thins mucus and boosts surfactant (mucoregulator effect from its ambroxol component). Together they improve airflow, ease expectoration and reduce breathlessness.
How should Truceb-E Tablet be taken?
Usual adult dose is 1 tablet twice daily after meals for 5–10 days, or as directed by your physician. Take with water; taking after food helps reduce any stomach upset. Complete the full prescribed course even if you start feeling better.
Is Truceb-E Tablet safe for long-term use?
Truceb-E is generally well tolerated for the durations typically prescribed in acute and sub-acute chest conditions. For longer maintenance therapy in chronic bronchitis or COPD, use should be reviewed periodically by your pulmonologist. Patients on other xanthine-containing medicines or on CYP1A2-inhibiting antibiotics should be monitored, as this can raise theophylline levels.
Who should NOT take Truceb-E Tablet?
Truceb-E should be avoided in patients with known hypersensitivity to Erdosteine, Acebrophylline, ambroxol or theophylline; severe hepatic impairment; severe cardiac arrhythmia; active peptic ulcer disease; uncontrolled hyperthyroidism; homocystinuria; and generally in children below 12 years. It should also be used with caution in seizure disorders and during pregnancy/lactation — always under specialist supervision.
Is Truceb-E Tablet available for PCD franchise?
Yes. Truceb-E Tablet is available from Trumac Healthcare for pan-India monopoly PCD (Propaganda Cum Distribution) pharma franchise and for third-party manufacturing under your own brand. We supply WHO-GMP manufactured stock with full QC documentation, batch COA and competitive net rates. Contact us on WhatsApp at +91 90416 77932 for pricing, packs and monopoly territory availability.
What is the packing?
Truceb-E Tablet is packed in Alu-Alu blister — 10 x 10 Tablets per box (10 blister strips of 10 tablets each = 100 tablets per outer). Alu-Alu packaging protects the tablets from moisture and light during Indian climatic transit.
How quickly can Trumac Healthcare dispatch a PCD order?
Routine PCD orders are dispatched within 48 hours of payment realisation, subject to stock availability and your distance from our depot. For monopoly partners we maintain buffer stock against forecasted monthly off-take.
Related Products